All News

Hepatitis B (Keep)

ICYMI: AGA Guideline: Prevention and Treatment of Hepatitis B Virus Reactivation in At-Risk Individuals

Jack Cush, MD

The American Gastroenterology Association has published its revised clinical practice guidelines for the prevention and treatment of hepatitis B virus (HBV) reactivation in at-risk patients, particularly those with immune-mediated disease, receiving immunomodulatory therapy and steroids.

Read Article
arthritis.RA_.Xray_.hands_.jpg (keep)

ICYMI: Is Rheumatoid Arthritis Becoming Milder?

Jack Cush, MD

A 24 year, prospective study analyzing very early rheumatoid arthritis (RA) in three consecutive eras suggests that RA has evolved since 2005, demonstrating less seropositivity, inflammation, and erosions but is characterized by more comorbidity, smoking and corticosteroid use.

Read Article
human figures on blue circle

ICYMI: Introducing Polyrefractory RA: A New Frontier in Difficult-to-Treat RA

Jiha Lee, MD

At a EULAR 2025 session titled “What makes ‘Difficult-to-treat RA’ so difficult to treat? And what can we do?”, Drs. Paula David and Dennis McGonagle introduced the emerging concept of polyrefractory rheumatoid arthritis (RA), a term now being used to describe a subset of patients who have failed to respond to five or more biologic or targeted synthetic DMARDs. This new classification, derived from recent multinational registry data, represents a significant step in refining our understanding and management of the most treatment-resistant forms of RA.

Read Article
holding hands together support frail

What we need in very early arthritis

David Liew, FRACP

It's easy to think that in our current world that we've done it all for rheumatoid arthritis, that there's nothing left to be done after b/tsDMARDs have become relatively widespread and accessible. If we aren’t satisfied that we’ve done all we can for our RA patients, how can we make their treatment and their lives better?

Read Article
JAK Inhibitors: The Latest from the JAK-pot Study Dr. David Liew reports on abstract POS0150 - Evolution of Janus Kinase Inhibitors (JAKi) Prescriptions Since 2015 In An International Collaboration of Rheumatoid Arthritis Registers (The 'JAK-pot' Study): Effect of Regulatory https://t.co/KiOZuphQTx
Dr. John Cush RheumNow ( View Tweet)
All Rheumatoid Arthritis is Not the Same Dr. Jonathan Kay reviews abstracts OP0323 and OP0328 from the EULAR 2025 meeting in Barcelona, Spain. https://t.co/rbK3Y1NHVI https://t.co/eYPdbx87kt

Links:

Dr. John Cush RheumNow ( View Tweet)
Rheumatoid Arthritis Panel: EULAR 2025 Panelists Drs. Mrinalini Dey, Janet Pope, Jonathan Kay and Jack Cush review RA studies and sessions presented at the 2025 EULAR meeting in Barcelona, Spain. Abstracts discussed: OP0004; OP0105; LB0006; OP0327; OP0330; OP0232; 0P0190. https://t.co/hmosUKOgTt
Dr. John Cush RheumNow ( View Tweet)
Jekyll and Hyde: which RA-ILD is it? Dr. David Liew reports on abstract OP0329 presented at the EULAR 2025 meeting in Barcelona, Spain. https://t.co/oH9nXaKRDz https://t.co/iUAJk2Q856

Links:

Dr. John Cush RheumNow ( View Tweet)
Prospective KORAIL study of 138 RA pts w/ ILD on chest CT -60% had UIP ILD. After F/U of 2.9 yrs, 35% had RA-ILD progression. Baseline predictors of progression = UIP, ILD >10 %, DLCO %pred, CCP+, KL-6 levels, RA Dz activity. Useful to ID high-risk RA-ILD pts.

Dr. John Cush RheumNow ( View Tweet)

What we need in very early arthritis It's easy to think that in our current world that we've done it all for rheumatoid arthritis, that there's nothing left to be done after b/tsDMARDs have become relatively widespread and accessible. If we aren’t satisfied that we’ve done all https://t.co/v8T3JQwuhM
Dr. John Cush RheumNow ( View Tweet)
Korean Health claims data study of 35,133 newly Dx, seropositive #RA pts (2011 to 2020) & 1,386 (3.9%) were Dx w/ new-onset stroke (CVA). Signif. lower risk of CVA w/ SSZ (aOR: 0.79) or HCQ (aOR: 0.83), but Increased risk w/ glucocorticoids (aOR: 1.71) & tocilizumab (aOR: 3.47) https://t.co/rPaj6cH74K
Dr. John Cush RheumNow ( View Tweet)
Using Veterans Affairs data (2006 - 2020) on RA-ILD patients, a target emulation trial showed no difference in mortality or respiratory hospitalization comparing RA-ILD Rx w/ either RTX, abatacept, tocilizumab, tofacitinib. Does this mean? they Dont Work or the Do Work? https://t.co/MkQmKsE3WQ
Dr. John Cush RheumNow ( View Tweet)
EULAR 2025 – RA Panel Discussion Leading experts in rheumatology dive into the latest advances, treatment strategies, and emerging research in rheumatoid arthritis. Don’t miss this in-depth panel as they unpack key findings from EULAR 2025 and discuss what’s next for RA care. https://t.co/hoxz0zWieN
Dr. John Cush RheumNow ( View Tweet)
UK study of 17472 newly Dx #RA pts (10997 MTX, 4,540 csDMARDs; 13680 steroids-CS) w/ 1307 Serious Infx (SI) (3/100PY) & 311 SI deaths. MTX signif decr. SI (adj HR 0.72) & CS no effect HR 0.99. SI assoc w/ age, smoker, comorbidity, seropositive, high DAS28. 1 DAS unit incr SI https://t.co/Zmsuaf7Rw3
Dr. John Cush RheumNow ( View Tweet)
Persistent Burden in Early RA Despite Disease Control: insights from CareRA Trials Advances in the treatment of rheumatoid arthritis (RA), particularly the treat-to-target strategy and the introduction of effective disease-modifying antirheumatic drugs (DMARDs), have improved https://t.co/cMiF6POKGS
Dr. John Cush RheumNow ( View Tweet)
Global burden of dz study - UN statistics show post-Menopausal women (PMW) are 20% of all women in 2021 (vs 13.7% 1990). From 1990 to 2021, the prevalence of MSK Dz in PMW significantly risen, especially for RA, OA, and gout. https://t.co/HdkopkxLdv https://t.co/wsGhg0P1tL

Links:

Dr. John Cush RheumNow ( View Tweet)
Survey of 154 Saudi established #RA pts on MTX >3mos; 64% claiming #MTX intolerance & 36% w/ MTX Intolerance Severity Score (MISS) >6. But MTX intolerance was NOT related to dose or route of administration, meal or time of day. These were not new MTX starters https://t.co/6KWGcZvx4o
Dr. John Cush RheumNow ( View Tweet)
Why is RA Difficult to Treat? Dr. Jonathan Kay shares his perspective on five posters presented at EULAR 2025 in Barcelona, Spain. Posters reviewed: POS0027, POS0028, POS0185, POS0030, POS0163 https://t.co/Ad4hVN21MJ https://t.co/d0BfQWjjL0

Links:

Dr. John Cush RheumNow ( View Tweet)
Does Abatacept Buy You Time Off RA? Dr. David Liew reports on abstract OP0325 presented at the 2025 EULAR meeting in Barcelona, Spain. https://t.co/t8NLvPjcju https://t.co/bloTKQ87rv

Links:

Dr. John Cush RheumNow ( View Tweet)
How to properly use steroids in early RA Guidelines differ on the early treatment of RA – ACR suggests not to use glucocorticoids (GC) and EULAR updated recommendations for RA treatment presented at #EULAR2025 continued to suggest early treatment with MTX and glucocorticoids. https://t.co/FakKxRot0p
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×